Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200 Day Moving Average - Here's What Happened

Key Points

• Xtant Medical's share price has crossed above its 200-day moving average, indicating potential momentum in the stock, trading at $0.55 with a high of $0.57.
• The company has a market capitalization of $76.77 million and institutional investors hold 69.33% of its stock, suggesting significant interest from larger entities.
• Renaissance Technologies LLC increased its holdings in Xtant Medical by 15.0%, acquiring additional shares during the fourth quarter, which could enhance investor confidence.

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.55 and traded as high as $0.57. Xtant Medical shares last traded at $0.55, with a volume of 14,574 shares.

Xtant Medical Price Performance

The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.03 and a current ratio of 2.34. The stock has a market capitalization of $84.99 million, a price-to-earnings ratio of -6.79 and a beta of -0.21. The business's 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.56.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC lifted its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 798,033 shares of the medical device company's stock after purchasing an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 69.33% of the company's stock.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.